To the Editor, [2] [3] [4] reported the use of these drugs in treatment of PML arising in 10 patients of hematological disorders or HIV infection. Seven of them improved to varying degrees, and as the editorial notes, 5 the presence of JC virusspecific T-cells in the blood appears to be a prerequisite for their use, something not reported in this case. Other success stories have appeared in recent literature. 6 These series however did not include any organ transplant patients, and it would be interesting to see whether CPi work in this group without significant adverse events. CPi are relatively contraindicated in patients on steroids [such as those with autoimmune disorders and organ transplant, as steroids may (theoretically) prevent the immune stimulation] but have been used in transplant patients for treatment of malignancies, with both tumor regression and graft rejection 7 . Hence, the risk to benefit ratio must be carefully considered before using CPi for PML in transplant patients. Interestingly, CPi themselves are associated with PML. 8 
